HER2-Positive Gastric Adenocarcinoma — Trials

HER2-Positive Gastric Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

43 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 15
Recruiting: 6
Ph III recruiting: 2
Growth YoY: —
Industry share: 40%
Top sponsor: Qilu Hospital of Shandong University
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (7)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05514717	A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2	terminated	Phase 1	57	Day One Biopharmaceuticals, Inc.INDUSTRY	1	Jun 18, 2026	clinicaltrials
NCT04727151	TAC T-cells for the Treatment of HER2-positive Solid Tumors(TACTIC-2)	terminated	Phase 1 / Phase 2	28	Triumvira Immunologics, Inc.INDUSTRY	2	Jun 8, 2025	clinicaltrials